Trommelmans Leen, Selling Joseph, Dierickx Kris
Faculty of Medicine, Centre for Biomedical Ethics and Law, Catholic University of Leuven, Leuven, Belgium.
Tissue Eng. 2007 Apr;13(4):667-72. doi: 10.1089/ten.2006.0089.
The development of tissue engineering in Europe suffers from the absence of a coherent regulatory framework. Therefore, the European Commission has drafted a directive to regulate all tissue-engineered products in a comprehensive yet flexible framework. This article analyzes the directive from an ethical viewpoint. We argue that there are shortcomings to the proposal because of disjunctures at various regulatory levels and because responsibilities of several authorities have not been clearly established. The conscious decision to exclude ethically sensitive issues from the regulation will contribute to a continued complex regulatory environment for tissue-engineered products in Europe. We suggest that, from the start, ethical issues must be considered as an integral part of the regulation of tissue-engineered products. We propose the development of a multistage regulatory framework that makes provision for the diversity of tissue-engineered products, whereby the hybrid character and the ethical sensitivity of these products are fully taken into account. We equally suggest that the general public remain involved in regulatory issues concerning tissue-engineered products.
欧洲组织工程学的发展因缺乏连贯的监管框架而受阻。因此,欧盟委员会起草了一项指令,以便在一个全面而灵活的框架内对所有组织工程产品进行监管。本文从伦理角度分析了该指令。我们认为,由于在各个监管层面存在脱节,且几个部门的职责尚未明确界定,该提案存在缺陷。有意识地决定将伦理敏感问题排除在监管范围之外,将导致欧洲组织工程产品的监管环境持续复杂。我们建议,从一开始就必须将伦理问题视为组织工程产品监管不可或缺的一部分。我们提议建立一个多阶段监管框架,以应对组织工程产品的多样性,充分考虑这些产品的混合特性和伦理敏感性。我们同样建议公众继续参与有关组织工程产品的监管问题。